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INTRODUCTION
Cancers involving the esophagus, gastroesophageal junction, and stomach (collectively referred to as esophagogastric cancer, EGC) are the second leading cause of cancer death worldwide (1) . While the identification and pharmacologic targeting of actionable molecular alterations have led to effective therapeutic strategies in many tumor types (2) (3) (4) , targeted therapies have yet to substantially impact the treatment of EGC. The only FDA-approved therapy targeting a specific molecular alteration in EGC is trastuzumab, a monoclonal antibody against the Human Epidermal Growth Factor Receptor 2 (HER2, ERBB2), which is approved in combination with chemotherapy for the ~20% of gastric and gastroesophageal junction cancers with HER2-amplification or overexpression. However, the addition of trastuzumab to chemotherapy produced only a modest improvement in survival and a 12% absolute increase in response rate (5) .
Therefore, the development of new therapeutic approaches that can effectively exploit key molecular targets in EGC is of critical clinical importance.
MET gene amplification and MET protein overexpression are observed in ~5% and ~50% of EGC, respectively (6, 7) . MET encodes a receptor tyrosine kinase (RTK), which is typically activated by its ligand, hepatocyte growth factor (HGF), and signals through downstream pathways involved in oncogenesis (8) . Although clinical efforts to target the MET pathway in EGC patients harboring MET protein overexpression have yielded disappointing results (9, 10) , there is evidence that MET-amplification (as opposed to protein overexpression only) may be a true oncogenic driver in EGC. METamplified EGC cell lines display exquisite sensitivity to MET inhibitors (11) , and patients with MET-amplified EGC have experienced tumor shrinkage after treatment with small molecule MET inhibitors or monoclonal antibodies against MET (12, 13) . Recently, a phase I clinical trial of the MET kinase inhibitor AMG337 in 13 patients with METamplified EGC demonstrated a 62% response rate (14) .
Thus, MET-amplification may represent a promising therapeutic target for EGC, but a better understanding of the clinical mechanisms of resistance to MET inhibition will be vital to the successful therapeutic implementation of these agents. Here, through molecular analyses of tumor biopsies from MET-amplified EGC patients treated with MET kinase inhibitors, we define key mechanisms of acquired and de novo resistance and identify important characteristics of EGC biology that may have broad implications for the use of targeted therapies in this disease.
RESULTS

Clinical acquired resistance to MET kinase inhibition
Robust and, in some cases, durable tumor responses to MET inhibition have been observed in some MET-amplified EGC patients (12) (13) (14) , but as with all targeted therapies, the inevitable emergence of acquired resistance limits clinical benefit.
Understanding the mechanisms of clinical acquired resistance to therapy may offer opportunities to overcome resistance and to prolong therapeutic response. Patient #1 was diagnosed with MET-amplified (4.3-fold) adenocarcinoma of the distal esophagus, and was treated with the experimental MET kinase inhibitor AMG337 (NCT01253707) following disease progression on first-line chemotherapy (14) . AMG337 is a highly selective small molecule MET kinase inhibitor, which was found to bind only to MET in a competitive binding assay conducted against 402 human kinases(15). The patient experienced a profound tumor response lasting two years, until he developed difficulty swallowing and was found to have disease progression at the site of his primary tumor (Fig. 1A) .
A biopsy of his primary tumor was obtained upon disease progression, and molecular analysis was performed on this specimen as well as on the original biopsy obtained from the same site at diagnosis. Both biopsies harbored MET-amplification, but the post-progression biopsy also harbored a KRAS G12D mutation that was not detected in the pre-treatment biopsy (Fig. 1B; Tables S1, S2) . KRAS mutation or amplification can occur in ~10% or ~7% of treatment-naïve EGCs, respectively (6) . The emergence of KRAS mutations has been observed as a cause of clinical acquired resistance to other RTK inhibitors, including anti-EGFR antibodies in colorectal cancer (16, 17) . Similarly, exogenous expression of KRAS G12D in a MET-addicted EGC cell line SNU638 conferred resistance to MET kinase inhibition with crizotinib (Fig. 1C) .
Although crizotinib is FDA-approved as an ALK inhibitor for ALK-rearranged lung cancer, it is also a highly potent inhibitor of MET, and responses to crizotinib have been observed in MET-amplified EGC patients (12) . KRAS G12D expression in SNU638 cells maintained signaling downstream of MET despite crizotinib treatment, as evidenced by sustained phosphorylation of ERK, ribosomal protein S6 (S6), and to a lesser degree AKT (Fig. 1D) . These data support KRAS mutation as the cause of acquired resistance to MET kinase inhibition in this patient.
RTK co-amplification drives de novo resistance
Despite the striking responses seen in some patients, not all patients with METamplified EGC respond to MET kinase inhibition. We sought to define the common mechanisms of de novo resistance to MET inhibition in order to guide potential therapeutic strategies to overcome resistance. Patient #2 was diagnosed with metastatic gastric adenocarcinoma, and standard HER2 testing revealed 7-fold HER2-amplification. The patient was initially treated with FOLFOX + trastuzumab for four months, followed by 5-FU and radiation, but developed new metastatic disease.
Additional molecular analysis of the patient's original biopsy revealed 5-fold METamplification, and the patient was treated with AMG337 (14) . Unfortunately, the patient's disease progressed rapidly despite treatment ( Fig. 2A) , requiring discontinuation of therapy after less than one month. Remarkably, multi-color FISH analysis for MET and HER2 showed that co-amplification of these genes existed simultaneously in the same tumor cells (Fig. 2B) . Thus, in this patient, co-amplification of two driver RTKs may have led to redundant activation of downstream signaling pathways, thereby driving resistance to MET kinase inhibition.
To determine how commonly RTK co-amplification might exist as a potential driver of de novo resistance in MET-amplified EGC, we evaluated publicly available data from The Cancer Genome Atlas (TCGA) study of EGC (6) (Fig. 3A) .
However, OE33 cells were highly sensitive to combined MET/HER2 inhibition with both drugs in combination. Consistent with these findings, the combination of crizotinib and lapatinib produced robust suppression of downstream signaling effectors, including phosphorylated ERK (P-ERK), P-AKT, and P-S6, whereas incomplete suppression was achieved with either drug alone (Fig. 3B) . Similarly, we found that exogenous HER2 overexpression in MET-addicted SNU638 cells conferred resistance to MET kinase inhibition with crizotinib, but that combined MET/HER2 inhibition could overcome resistance (Fig. 3C) . HER2 overexpression led to maintenance of P-ERK, P-AKT, and P-S6 in the presence of crizotinib alone, but the combination of crizotinib and lapatinib retained the ability to suppress phosphorylation of these downstream effectors (Fig. 3D) .
These data suggest that RTK co-amplification can lead to redundant activation of downstream effector pathways and that combined RTK inhibition may be required to restore sensitivity. however, her disease progressed rapidly through treatment. More extensive molecular analysis of her biopsy revealed that her tumor harbored >25-fold amplification of both HER2 and MET present in the same tumor cells (Fig. 3E) , likely explaining why her disease progressed despite trastuzumab-containing chemotherapy. Accordingly, the patient was treated with the combination of trastuzumab, crizotinib, and weekly paclitaxel (as described in Methods), which the patient tolerated well with some increased peripheral edema. Strikingly, a repeat PET-CT scan performed 2 months after initiation of therapy revealed near-complete resolution of her disease (Fig. 3F) . This case suggests that co-amplification of MET and HER2 led to resistance to anti-HER2 therapy alone, but that, consistent with the in vitro results above, combined MET/HER2 inhibition led to a dramatic clinical response. Of note, the patient's tumor did not harbor rearrangements in ALK or ROS1, which are known to confer sensitivity to crizotinib in non-small cell lung cancer ( Figure S1 ) (2, 4) . Although a contribution of paclitaxel to the response cannot be excluded, this is less likely given that clinical evidence of response occurred rapidly, before substantial exposure to paclitaxel, and that the patient's disease had progressed rapidly through combination cytotoxic chemotherapy in the prior line of therapy. Based on these data, combined RTK inhibition may be an effective therapeutic strategy for EGCs harboring RTK co-amplification and warrants further clinical investigation.
Heterogeneity as a driver of resistance and mixed response in EGC
Patient #4 presented with shoulder pain and was found to have widespread bone metastases. Biopsy of a right scapular lesion established the diagnosis of adenocarcinoma, and endoscopy revealed a primary gastric cancer. Molecular analysis was performed on his scapular biopsy and revealed >25-fold MET-amplification. The patient was treated with AMG337, but after less than a month, he developed decreased oral intake and shortness of breath (14) . He was found to have new ascites and pleural effusion, and endoscopy confirmed progression of his gastric mass. Imaging revealed the development of new liver metastases, but surprisingly also showed that his bone metastases had responded to therapy (Fig. 4A) .
To determine the cause of this mixed response to therapy, we performed molecular analyses on additional tumor biopsies obtained from this patient during the course of his clinical care. Prior to initiating therapy, a biopsy of his primary gastric tumor had also been obtained. However, since it is not standard clinical practice to perform molecular analysis on more than one biopsy from the same patient at diagnosis, this specimen had not undergone molecular testing, and only the scapular biopsy was initially analyzed. Surprisingly, retrospective analysis of his pre-treatment gastric biopsy showed no evidence of MET-amplification, but rather showed low-level HER2-amplification ( Fig. 4A) . Importantly, despite differences in gene amplification, both the scapular biopsy and the primary tumor harbored the same TP53 R158H mutation, (20, 21) . Peripheral blood was collected at baseline and throughout MET inhibitor therapy, and ddPCR was used to monitor the levels of specific molecular alterations present in ctDNA (Fig. 4C) . Levels of shared "truncal" mutations (in TP53 and SMAD4)
decreased initially with treatment but rose upon disease progression, and largely paralleled the overall levels of cell-free DNA. Conversely, elevated MET copy number detectable in ctDNA decreased to near-normal levels during the first two months of (Table   S3 ). While small patient numbers limit any definitive conclusions, these data suggest that it may be important to confirm the presence of RTK amplification in the primary tumor prior to initiation of targeted therapy in EGC. Overall, the potential for molecular heterogeneity appears to play a key role in drug resistance with several important diagnostic and therapeutic implications.
DISCUSSION
MET inhibition can lead to striking, and at times durable, responses in some patients with MET-amplified EGC, and represents a promising therapeutic strategy (12) (13) (14) . The validity of MET as a therapeutic target in EGC has been questioned based on recent negative Phase III studies targeting this pathway in EGC(9, 10). However, these studies were not conducted specifically in the MET-amplified EGC population, and the majority of patients treated had MET protein overexpression only. One possible explanation is that the immunohistochemistry threshold used to define MET overexpression may not be stringent enough to identify those patients whose tumors are truly dependent on MET signaling. Alternatively, since MET-amplification involves a genetic change, it is perhaps more likely to represent a driving event upon which the tumor is dependent, compared to MET protein overexpression only, which may result as a consequence of other mechanisms within the tumor cell, making it less likely to be a driving molecular event. Thus, the therapeutic potential for MET inhibition may be limited to EGC patients with MET-amplification, and these clinical trials underscore how critical appropriate patient selection may be to the successful clinical implementation of MET inhibitors.
We evaluated the causes of acquired and de novo resistance to MET kinase inhibition in MET-amplified EGC to better understand the clinical factors influencing the efficacy of these agents. While the patients in this study were treated with a small molecule MET kinase inhibitor, tumor responses in MET-amplified EGC patients have also been observed with anti-MET antibodies(13), so it is likely that the resistance mechanisms we identified may be relevant to these agents, as well. We report here the first mechanism of clinical acquired resistance to be identified in a MET-amplified EGC patient, which followed a two-year response to a MET kinase inhibitor. Acquired resistance in this patient was driven by the emergence of a KRAS mutation, which can bypass pathway suppression by a MET inhibitor. A detailed understanding of additional mechanisms that can drive clinical acquired resistance in MET-amplified tumors may guide future therapeutic strategies to overcome resistance. We also sought to understand causes of de novo resistance to explain why some patients fail to respond to MET inhibition altogether. Our study revealed two unique characteristics of EGC that appear to play key roles in therapeutic resistance. Fig. 3F ). Collectively, these observations suggest that comprehensive molecular analyses (as opposed to single biomarker assessment, as is the current diagnostic standard for HER2 testing) should be performed prior to selection of a targeted therapy strategy for EGC patients to identify potential co-occurring driver alterations that might preclude efficacy. Furthermore, these data suggest that RTK inhibitor combinations or dual-targeting agents directed against multiple RTKs may warrant clinical evaluation in EGC.
Additionally, we observed that dramatic heterogeneity in MET-amplification can occur between different metastatic lesions and the primary tumor in individual EGC patients, leading to mixed responses to MET kinase inhibition and treatment failure due to outgrowth of non-MET-amplified clones. We also found that similar heterogeneity can be observed in patients with HER2-amplified disease (Fig. 4D, Fig. S3 MET copy gain observed in ctDNA from Patient #5 (Fig. 4C) . Interestingly, our small cohort of MET-amplified patients suggested that patients with MET-amplification detected in their primary tumors derived greater clinical benefit from MET kinase inhibition, though small patient numbers limit a definitive correlation (Table S3 ). This suggests that testing of the primary tumor may identify patients in whom METamplification arose as an earlier event, and thus whose overall tumor burden may more likely be MET-dependent. In summary, we find that frequent RTK co-amplification and heterogeneity of RTK-amplification are key molecular features driving lack of benefit from MET inhibition (and perhaps other targeted therapies) in EGC patients. Thus, comprehensive molecular analysis to detect potential concurrent RTK gene amplifications should be performed prior to initiation of targeted therapy, and targeted therapy combinations may be needed.
Furthermore, due to the potential for molecular heterogeneity within an individual EGC patient, concurrent molecular analysis of all available biopsy specimens, particularly the primary tumor, should be considered prior to initiation of therapy to identify patients in whom RTK-amplification is most likely to represent an early driving molecular event.
These important characteristics of EGC biology may have important clinical implications for the development of targeted therapy strategies for this disease.
METHODS
Patient samples, cell lines, and reagents
Patient tumor and blood specimens were obtained from patients treated at the Massachusetts General Hospital under Institutional Review Board-approved studies.
For patients with multiple blood or tumor samples analyzed, DNA fingerprinting by short tandem repeat (STR) analysis (BioSynthesis, Lewisville, TX) was performed to confirm that samples originated from the same patient. All patients provided written, informed consent, and studies were conducted in accordance with the Declaration of Helsinki.
Patient #3 was treated with crizotinib 250mg orally twice daily, trastuzumab 6mg/kg intravenously every three weeks, and weekly paclitaxel 80mg/m 2 (beginning the second week of treatment) off-label with informed consent.
OE33 and SNU638 cells were obtained from the Massachusetts General
Hospital Center for Molecular Therapeutics, which performs routine cell line authentication testing by single-nucleotide polymorphism and STR analysis, and were passaged less than six months following receipt. Cells were grown in RPMI (GIBCO) with 10% FBS and assayed in DMEM/F12 with 5% FBS. Crizotinib and lapatinib (Selleck Chemicals) were dissolved in DMSO.
Fluoresence in situ hybridization (FISH)
Standard FISH for MET, HER2, and EGFR and break-apart FISH assays for the detection of ALK or ROS1 rearrangements(2, 4) were performed in the Massachusetts specifications. Antibodies for MET, P-MET (Y1234/1235) HER2, P-HER2 (Y1221/1222), P-AKT (S473), and P-S6 (S240/244), (Cell Signaling) were used at 1:1000 dilution; P-ERK (Cell Signaling) was used at 1:2000 dilution. GAPDH (Millipore) was used at 1:1000 dilution. Protein detection on Western blots was performed using SuperSignal chemiluminescence (Thermo Scientific).
Determination of relative cell titer
For in vitro viability assays, cells were plated onto parallel 96-well plates at 2,000 cells/well in RPMI (GIBCO) with 5% FBS. After 24 hours, serial dilutions of inhibitor were added to the wells. Plates were incubated for 3 days, and cell titer was measured by
CellTiter-Glo assay (Promega). Relative cell titer was calculated as a percent of the value for cells without inhibitor treatment. Nonlinear regression curves were calculated and displayed using GraphPad Prism 5.
Plasmids
Wild-type MET (23889) and HER2 (23888) in pDONR223 were obtained from Addgene. cDNAs were transferred to the pLenti CMV Puro DEST (Addgene 17452) expression vector using LR Clonase II (Life Technologies).
Lentiviral infections
Transfection complexes containing the lentiviral expression vector and packaging plasmids psPAX2 and pVSVG were assembled using TransIT-LT1 Transfection Reagent (Mirus) and added to 293T cells for production of lentiviral supernatant. All infections were performed in the presence of polybrene (8µg/mL). Following addition of lentiviral supernatants, cells were centrifuged for 1 hour at 2500rpm. After 24 hours, growth medium containing 1µg/mL puromycin (Sigma) was added for 72 hours to select for a stable population of infected cells.
Plasma Collection
At least 10 mL of whole blood was collected by peripheral blood draw using EDTA as an anticoagulant. Plasma was separated within 4 hours through 2 different centrifugation steps (the first at room temperature for 10 minutes at 1,600 x g and the second at 3,000
x g for the same time and temperature), obtaining up to 3 mL of plasma. Plasma was stored at -80°C until ctDNA extraction.
ctDNA isolation and quantification of genome equivalents ctDNA was extracted from plasma using the QIAamp Circulating Nucleic Acid Kit (QIAGEN) according to the manufacturer's instructions. 6 μL of ctDNA were used as template for each reaction. All samples were analyzed in triplicate. PCR reactions were performed using 10 μL final volume containing 5 μL GoTaq qPCR Master Mix, 2X with CXR Reference Dye) (Promega) and LINE-1 [12.
5 μmol] forward and reverse primers.
DNA at known concentrations was also used to build the standard curve. Primer sequences are available upon request.
Droplet digital PCR analysis
Isolated circulating free DNA was amplified using ddPCR™ Supermix for Probes (BioRad) using KRAS p.G12D (PrimePCR™ ddPCR™ Mutation Assay, Bio-Rad), TP53 
